BACE Inhibitor Structural Modifications for Potency and Cardiovascular Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current BACE inhibitors, such as those described in WO2012/085038 and WO2012/120023, have limitations in potency and cardiovascular profile, necessitating the development of more effective 5,6-dihydroimidazo[1,5-a]pyrazinyl derivatives for treating Alzheimer's disease and related disorders.
Innovation Solution
Development of 5,6-dihydroimidazo[1,5-a]pyrazinyl derivatives with specific structural modifications, including various substituents and stereoisomeric forms, which act as potent inhibitors of BACE1 and/or BACE2, formulated into pharmaceutical compositions for treating Alzheimer's disease, mild cognitive impairment, and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current BACE inhibitors are used, then Alzheimer's disease treatment is provided, but potency and cardiovascular profile are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of BACE inhibitors through various substitutions at positions R1, R2, R3, R4, and R5, as well as changing the aromatic ring systems. These structural parameter changes result in compounds with improved potency (lower IC50 values) and better cardiovascular profiles compared to prior art inhibitors.
Solution Approach 2:
The patent employs composite material principles by creating complex fused ring systems combining imidazo[1,5-a]pyrazine cores with various aromatic substituents (pyridine, pyrimidine, indole, quinoline rings). This composite structural approach allows optimization of both potency and cardiovascular safety profiles simultaneously.
2Reliability
If structural modifications are made to improve potency, then BACE inhibition is enhanced, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core 5,6-dihydroimidazo[1,5-a]pyrazinyl portion and separate aromatic substituent portions. This modular segmentation allows systematic optimization of potency through substituent variation while maintaining a consistent core structure, thereby managing overall complexity.
Solution Approach 2:
The patent implements local quality by introducing specific substituents at particular positions (R1-R5) on the core structure. Each position can be independently optimized with specific functional groups or aromatic systems tailored to enhance BACE binding affinity at the active site, while the core structure remains relatively simple and manageable.
Data Source
AI summary
The present invention relates to novel 5,6-dihydroimidazo[1,5-a]pyrazinyl derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, in particular BACE1 and/or BACE2 (wherein BACE1, is also known as Asp2, or memapsin2 and BACE2 is also known as Asp1, Memapsin 1 or DRAP). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, dementia of the Alzheimer's type, dementia associated with beta-amyloid, age-related macular degeneration, type 2 diabetes and other metabolic disorders.